Structure of the HIV immature lattice allows for essential lattice remodeling within budded virions.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
12 07 2023
Historique:
received: 12 11 2022
accepted: 12 07 2023
medline: 24 7 2023
pubmed: 12 7 2023
entrez: 12 7 2023
Statut: epublish

Résumé

For HIV virions to become infectious, the immature lattice of Gag polyproteins attached to the virion membrane must be cleaved. Cleavage cannot initiate without the protease formed by the homo-dimerization of domains linked to Gag. However, only 5% of the Gag polyproteins, termed Gag-Pol, carry this protease domain, and they are embedded within the structured lattice. The mechanism of Gag-Pol dimerization is unknown. Here, we use spatial stochastic computer simulations of the immature Gag lattice as derived from experimental structures, showing that dynamics of the lattice on the membrane is unavoidable due to the missing 1/3 of the spherical protein coat. These dynamics allow for Gag-Pol molecules carrying the protease domains to detach and reattach at new places within the lattice. Surprisingly, dimerization timescales of minutes or less are achievable for realistic binding energies and rates despite retaining most of the large-scale lattice structure. We derive a formula allowing extrapolation of timescales as a function of interaction free energy and binding rate, thus predicting how additional stabilization of the lattice would impact dimerization times. We further show that during assembly, dimerization of Gag-Pol is highly likely and therefore must be actively suppressed to prevent early activation. By direct comparison to recent biochemical measurements within budded virions, we find that only moderately stable hexamer contacts (-12

Identifiants

pubmed: 37435945
doi: 10.7554/eLife.84881
pii: 84881
pmc: PMC10361719
doi:
pii:

Substances chimiques

Gene Products, gag 0
Peptide Hydrolases EC 3.4.-
Endopeptidases EC 3.4.-
gag Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI150474
Pays : United States
Organisme : NIH HHS
ID : R01 AI150474
Pays : United States

Déclaration de conflit d'intérêts

SG, IS, SS, MJ No competing interests declared

Références

J Chem Phys. 2019 Sep 28;151(12):124115
pubmed: 31575182
Science. 2016 Jul 29;353(6298):506-8
pubmed: 27417497
J Mol Biol. 2023 Aug 1;435(15):168143
pubmed: 37150290
J Chem Phys. 2015 Aug 28;143(8):084117
pubmed: 26328828
Viruses. 2021 Sep 28;13(10):
pubmed: 34696376
J Am Chem Soc. 2022 Jun 15;144(23):10417-10428
pubmed: 35666943
J Mol Biol. 2011 Feb 18;406(2):205-14
pubmed: 21134384
Nature. 2008 Oct 2;455(7213):693-6
pubmed: 18833280
J Mol Biol. 2007 Jan 19;365(3):799-811
pubmed: 17098251
Adv Chem Phys. 2014;155:1-68
pubmed: 25663722
Biophys J. 2020 Aug 4;119(3):581-592
pubmed: 32652060
J Virol. 2016 Aug 26;90(18):8074-84
pubmed: 27356903
Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Aug;72(2 Pt 1):021917
pubmed: 16196614
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):E10056-E10065
pubmed: 29114055
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11364-9
pubmed: 16840558
Science. 2021 Aug 6;373(6555):700-704
pubmed: 34353956
Elife. 2021 Jun 11;10:
pubmed: 34114563
Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19114-9
pubmed: 19861549
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11090-5
pubmed: 19549863
Nat Chem. 2010 Jun;2(6):472-7
pubmed: 20489716
Phys Rev X. 2014 Jul-Sep;4(3):
pubmed: 26005592
Annu Rev Virol. 2014 Nov;1(1):561-80
pubmed: 26958734
Sci Adv. 2022 Jul 8;8(27):eabn9874
pubmed: 35857464
J Virol. 2020 Feb 14;94(5):
pubmed: 31801870
Proc Natl Acad Sci U S A. 2021 Dec 14;118(50):
pubmed: 34873042
PLoS Pathog. 2016 Jun 09;12(6):e1005657
pubmed: 27280284
ACS Nano. 2016 Sep 27;10(9):8215-22
pubmed: 27517329
J Phys Chem B. 2018 Dec 13;122(49):11771-11783
pubmed: 30256109
PLoS Comput Biol. 2022 Mar 21;18(3):e1009969
pubmed: 35312692
Trends Biochem Sci. 2011 Jul;36(7):373-80
pubmed: 21550256
RNA. 2013 Aug;19(8):1078-88
pubmed: 23798665
Retrovirology. 2006 Nov 03;3:77
pubmed: 17083721
Sci Adv. 2021 Mar 10;7(11):
pubmed: 33692109
Curr Opin Virol. 2021 Oct;50:128-138
pubmed: 34464843
J Biol Chem. 2012 Nov 30;287(49):40867-74
pubmed: 23043111
Biophys J. 2020 Jun 16;118(12):3026-3040
pubmed: 32470324
Nat Struct Biol. 1999 Sep;6(9):868-75
pubmed: 10467100
Viruses. 2022 Feb 08;14(2):
pubmed: 35215933
J Chem Phys. 2021 May 21;154(19):194101
pubmed: 34240891
mBio. 2021 Dec 21;12(6):e0325421
pubmed: 34872357
Viruses. 2020 Aug 26;12(9):
pubmed: 32858867
Soft Matter. 2021 Dec 8;17(47):10649-10663
pubmed: 34792524
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3213-7
pubmed: 2014242
Virology. 2015 May;479-480:403-17
pubmed: 25816761
Cell. 1989 Oct 6;59(1):103-12
pubmed: 2676191
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10875-9
pubmed: 11526217
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):
pubmed: 33397805
Elife. 2023 Jan 23;12:
pubmed: 36688533
Cell Rep. 2019 Dec 17;29(12):3983-3996.e4
pubmed: 31851928
J Virol. 2004 Aug;78(16):8477-85
pubmed: 15280456
J Biol Chem. 2020 Oct 16;295(42):14391-14401
pubmed: 32817318
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14545-50
pubmed: 26553975
Elife. 2018 Jun 07;7:
pubmed: 29877795
Biophys J. 2001 Jun;80(6):2987-99
pubmed: 11371471
Nature. 2015 Jan 22;517(7535):505-8
pubmed: 25363765
Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14889-94
pubmed: 15465916
Nature. 2018 Nov;563(7731):E22
pubmed: 30158708
Phys Biol. 2010 Dec 09;7(4):045003
pubmed: 21149971
J Virol. 2011 Feb;85(4):1420-8
pubmed: 21106735
Chem Biol. 2013 Apr 18;20(4):549-57
pubmed: 23601644
J Virol. 2000 Jul;74(13):5845-55
pubmed: 10846064
Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006924
pubmed: 22762019
Biophys J. 2023 Jun 30;:
pubmed: 37393432
Nat Commun. 2016 May 13;7:11568
pubmed: 27174390
PLoS Comput Biol. 2018 Mar 5;14(3):e1006031
pubmed: 29505559
J Virol. 2009 Aug;83(15):7718-27
pubmed: 19457986
Biophys J. 2002 Aug;83(2):1217-30
pubmed: 12124301
Nat Rev Microbiol. 2015 Aug;13(8):484-96
pubmed: 26119571
Biophys J. 2010 Nov 3;99(9):2757-65
pubmed: 21044572
Proc Natl Acad Sci U S A. 1989 Aug;86(15):5781-5
pubmed: 2788277
J Virol. 2016 Jul 11;90(15):6906-6917
pubmed: 27194769
EMBO J. 2007 Apr 18;26(8):2218-26
pubmed: 17396149
Biophys J. 2014 Jan 7;106(1):310-20
pubmed: 24411263
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5246-51
pubmed: 11320254
ACS Nano. 2022 Sep 27;16(9):13845-13859
pubmed: 36054910

Auteurs

Sikao Guo (S)

TC Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, United States.

Ipsita Saha (I)

Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, United States.

Saveez Saffarian (S)

Center for Cell and Genome Science, University of Utah, Salt Lake City, United States.
Department of Physics and Astronomy, University of Utah, Salt Lake City, United States.
School of Biological Sciences, University of Utah, Salt Lake City, United States.

Margaret E Johnson (ME)

TC Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH